Secondary Prevention Medications in 17 Countries Grouped by Income Level (PURE)

This publication has 24 references indexed in Scilit:

• Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries
  JAMA, 2023
• Trends in Provision of Medications and Lifestyle Counseling in Ambulatory Settings by Gender and Race for Patients With Atherosclerotic Cardiovascular Disease, 2006-2016
  JAMA Network Open, 2023
• Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016
  JAMA Network Open, 2020
• Management of blood pressure in stroke
  International Journal of Cardiology Hypertension, 2019
• The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5)
  JACC, 2019
• Multifaceted Intervention to Improve Medication Adherence and Secondary Prevention Measures After Acute Coronary Syndrome Hospital Discharge
  JAMA Internal Medicine, 2014
• Prospective Urban Rural Epidemiology (PURE) study: Baseline characteristics of the household sample and comparative analyses with national data in 17 countries
  American Heart Journal, 2013
• Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey
  The Lancet, 2011
• The Prospective Urban Rural Epidemiology (PURE) study: Examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries
  American Heart Journal, 2009
• Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
  The Lancet, 2001